How many drugs treat Complicated Proteus UTI?

Drug Landscape tracks 10 marketed treatments for Complicated Proteus UTI (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-proteus-uti.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Complicated Proteus UTI — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complicated Proteus UTI (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Proteus UTI, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Cystadane	BETAINE	Recordati	Methylating Agent [EPC]		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Cystadane	Cystadane	Mayo Clinic

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Complicated Proteus UTI
Pai Holdings Pharm · 2 drugs in Complicated Proteus UTI
Baxter · 2 drugs in Complicated Proteus UTI
Bayer AG · 1 drug in Complicated Proteus UTI
Bristol-Myers Squibb · 1 drug in Complicated Proteus UTI
Mayo Clinic · 1 drug in Complicated Proteus UTI
Novartis · 1 drug in Complicated Proteus UTI
Pfizer · 1 drug in Complicated Proteus UTI
Poitiers University Hospital · 1 drug in Complicated Proteus UTI
Recordati · 1 drug in Complicated Proteus UTI
Tel-Aviv Sourasky Medical Center · 1 drug in Complicated Proteus UTI
University Hospital Tuebingen · 1 drug in Complicated Proteus UTI

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Proteus UTI:

Cite this brief

Drug Landscape (2026). Complicated Proteus UTI — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-proteus-uti. Accessed 2026-06-10.

Complicated Proteus UTI full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing